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ybrid Cardiovascular Procedures
ohn G. Byrne, MD, FACC, Marzia Leacche, MD, Douglas E. Vaughan, MD, FACC,
avid X. Zhao, MD, FACC
ashville, Tennessee
hybrid strategy combines the treatments traditionally available only in the catheterization laboratory
ith those traditionally available only in the operating room to offer patients the best available thera-
ies for any given set of cardiovascular lesions. Examples include hybrid coronary revascularization
coronary artery bypass grafting [CABG]/percutaneous coronary intervention [PCI]) wherein a left inter-
al mammary artery graft is placed on the left anterior descending artery (left anterior descending coro-
ary artery [LAD]) either by minimally invasive or open technique and combined with PCI of non-LAD ves-
els. Other examples include minimally invasive valve surgery combined with PCI to coronary lesions (valve/
CI), to convert a high-risk valve/CABG into a lower-risk isolated minimally invasive valve procedure. Several
uestions remain unresolved, such as the order in which surgery and PCI should be performed, the dura-
ion of the staging of the 2 procedures, antiplatelet strategies, the costs, and the logistics. Other areas in
hich hybrid approaches are being developed include hybrid endomyocardial/epicardial atrial ﬁbrillation
rocedures and hybrid aortic arch debranching combined with endovascular grafting for thoracic aortic
rocedures. The key requirement in all of these approaches is the need for collaboration between cardiac
urgeons, vascular surgeons, and interventional cardiologists to obtain optimal patient outcomes. (J Am
oll Cardiol Intv 2008;1:459–68) © 2008 by the American College of Cardiology Foundationm
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vhybrid strategy combines the treatments tradi-
ionally available only in the catheterization labo-
atory with those traditionally available only in the
perating room, to offer patients the best available
ombination of treatments for any given set of
ardiovascular lesions. The concept is not new
1,2). Cardiac surgeons and interventional cardiol-
gists have been performing hybrid procedures
ince the first percutaneous intervention was fol-
owed later by a cardiac surgical procedure. When
estenosis after percutaneous coronary intervention
PCI) was more frequent than the modern PCI
esults, hybrid procedures were common, only they
ere staged by days, weeks, or perhaps months. In
he modern era, a hybrid procedure refers to the
ombination of traditional surgery and percutane-
us intervention, staged by minutes, hours, or at
rom The Vanderbilt Heart and Vascular Institute, Nashville,
ennessee.a
anuscript received May 27, 2008; revised manuscript received July 8,
008, accepted July 12, 2008.ost, days. This more compressed staging of
ybrid procedures has regained interest as cardiac
urgeons have improved techniques for minimally
nvasive surgical approaches, while interventional
ardiologists have at their disposal improved de-
ices and have developed skills that have enabled
hem to become more aggressive in their percuta-
eous interventions. Whereas interventional cardi-
logists are becoming “surgeons” with more inva-
ive tools, surgeons are becoming “interventional
ardiologists” with less invasive tools. Hence, the
ivision between the 2 specialties has become
lurred, and we are meeting in the middle. With
he increased complexity of patients referred to the
atheterization laboratory and to surgery, a team
pproach combining the best available tools of
oth specialties seems appealing to minimize the
rocedural risk. Examples of hybrid strategies in-
lude hybrid coronary artery bypass grafting
CABG)/PCI, hybrid valve/PCI, percutaneous
alve therapy, hybrid endocardial and epicardial
trial fibrillation (AF) procedures, and aortic de-
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460ranching procedures combined with endovascular grafting
or the treatment of complex thoracic aortic dissections or
neurysmal disease.
ybrid CABG/PCI
ybrid CABG/PCI is broadly defined as the combination
f traditional surgical methods with PCIs. Examples in-
lude everything from the common scenario PCI of a culprit
oronary lesion during an acute coronary syndrome followed
y conventional CABG during the same hospitalization, to
lective minimally invasive left internal mammary artery
LIMA) to the left anterior descending artery (LAD) with
CI to non-LAD lesions. The latter strategy attempts to
combine the best aspects of
CABG (the LIMA–LAD graft)
with the best aspects of PCI. In
minimally invasive direct coronary
artery bypass grafting (MID-
CAB), the LIMA is harvested
through a small left anterior tho-
racotomy incision or lower hemi-
sternotomy. The LIMA–LAD
bypass is crafted through this lim-
ited incision on the beating heart
(Figs. 1A and 1B). In 1996, An-
gelini et al. (1), in a series of 6
patients, reported the first series of
MIDCAB LIMA–LAD, com-
bined with percutaneous translu-
minal coronary angioplasty/stent
to non-LAD vessels.
Closed-chest CABG surgery
is performed with robotic sys-
tems, which allows manipulation
of tissues within thoracic ports
through the use of fine instru-
ments and peripheral institu-
tion of cardiopulmonary bypass.
At a separate operating console,
he surgeon controls the instruments, while the operation is
iewed stereoscopically (3-dimensional view). In 1999,
oulmet et al. (2) introduced totally endoscopic coronary
rtery bypass grafting (TECAB) of the LIMA–LAD using
eripheral access for cardiopulmonary bypass. Later in 2000,
arhat et al. (3) performed the first TECAB with LIMA-
AD, and PCI to the left circumflex system.
ationale, Indications, and Contraindications
f Hybrid CABG/PCI
everal trials have compared the outcomes of CABG
urgery versus PCI in multivessel disease (4). In a recent
bbreviations
nd Acronyms
F  atrial fibrillation
MS  bare-metal stent(s)
ABG  coronary artery
ypass grafting
ES  drug-eluting stent(s)
AD  left anterior
escending coronary artery
IMA  left internal
ammary artery
IDCAB  minimally
nvasive direct coronary
rtery bypass grafting
PCAB  off-pump coronary
rtery bypass
CI  percutaneous
oronary intervention
VG  saphenous vein graft
ECAB  totally endoscopic
oronary artery bypass
rafting
LR  target lesion
evascularizationeview of 23 randomized studies comparing PCI andABG, survival at 10 years was similar even among the
iabetic population; however, the rate of repeat revascular-
zation rate was higher than CABG along with lower rate of
elief from angina (5). Only 1 study included in the review
sed drug-eluting stents (DES), which were introduced in
003. Therefore, the majority of studies comparing the
utcomes of CABG and PCI were done using bare-metal
tents (BMS). Conversely, in a recent analysis of a large
egistry from New York state, CABG provided survival
dvantage and lower rates of myocardial infarction and
epeat revascularization even when compared with DES at
8-month follow-up (6). The LIMA–LAD graft has excel-
ent patency rates, which correlates with increased event-
ree survival. Recent reports suggest a 5-year patency rate
etween 92% and 99% (7–9) and at 10 years between 95%
nd 98% (10,11). The LIMA-LAD graft may be responsi-
le for the majority of the benefit of CABG surgery.
Figure 1. Minimally Invasive Direct Coronary Artery Bypass Grafting
(A) Minimally invasive direct coronary artery bypass grafting (MIDCAB)
of the left internal mammary artery (LIMA) to left anterior descending coro-
nary artery (LAD) through an anterior-lateral left thoracotomy on the beat-
ing heart. (B) Postoperative incision after MIDCAB.
W
g
t
c
t
i
n
n
r
d
r
o
5
b
(
t
s
S
r
w
l
t
b
t
t
T
h
f
c
r
l
s
t
o
d
o
s
R
R
r
w
s
a
(
c
l
f
r
T
m
l
W
o
l
J
u
m
M
o
p
l
t
c
m
b
d
I
r
c
p
9
A
s
w
i
(
e
e
o
w
C
y
R
W
(
a
e
m
t
l
l
b
(
a
e
2
A
t
2
d
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 5 , 2 0 0 8
O C T O B E R 2 0 0 8 : 4 5 9 – 6 8
Byrne et al.
Hybrid Cardiovascular Procedures
461hether non-LAD vessels are treated with saphenous vein
rafts (SVGs), PCI, or other modalities may be less impor-
ant. This is the premise on which the modern era of hybrid
oronary revascularization is based. Conversely, with PCI,
he location of the lesion in the proximal LAD has been
dentified as an independent risk factor for in-stent reste-
osis with rates between 19% and 44% (12,13).
The second conduit used after the LIMA to bypass
on-LAD vessels is the SVG, although the radial artery and
ight internal mammary artery are used as alternative con-
uits in selected patients. Failure rates for SVGs have been
eported at 1 year between 1.6% and 30%, with an average
f 20% (7,14,15). At 10 to 15 years of follow-up, 40% to
0% of the SVGs will have failed (11). These numbers may
e compared with the rate of target lesion revascularization
TLR) in non-LAD vessels for stents. In the era of BMS,
he TLR for proximal right/circumflex coronary artery
tents has been reported to be 13.8% at 1 year (16). The
IRIUS (Sirolimus-eluting Stent Implantation) trial has
eported a TLR rate at 2 years follow-up of 5.8%, compared
ith 21.3% in the control group (BMS) (17). These data are
ikely to improve in the near future with advances in DES
echnology that have narrowed the “reintervention gap”
etween surgery and PCI (18,19). Therefore, it is reasonable
o hypothesize that PCI with DES is a better treatment to
he non-LAD coronary artery disease than an SVG.
Indications for hybrid CABG/PCI (MIDCAB and
ECAB) include patients with multivessel disease who
ave high-grade proximal disease of the LAD along with
avorable lesions for PCI in the left circumflex and right
oronary artery territories. Other areas where PCI may
epresent a superior alternative to SVG conduit include the
ack or poor quality of the conduit, a nongraftable but
tentable vessel (e.g., left circumflex lesions in the atrioven-
ricular groove with small diffuse obtuse marginal), repeat
perations in which PCI is preferable to avoid full cardiac
issection, or in patients with concomitant pre-existing
rgans dysfunction, or recent myocardial infarction, or
evere atherosclerotic aortic disease.
esults of Hybrid CABG/PCI
esults for coronary hybrid revascularization are summa-
ized in Table 1. Hybrid coronary revascularization is safe
ith low mortality rates (0% to 2%), low morbidity, and
horter intensive care unit and hospital stay. Other clear
dvantages are superior cosmetic results and faster recovery
1,3,20–38).
Despite these encouraging results, hybrid coronary revas-
ularization is still reserved for few patients. To date, the
argest series of patients from a single institution accounts
or 70 patients enrolled over a 7-year period (31). This
epresents 5% of the center workload for CABG surgery.
he reasons for the low recruitment include limitations of hinimally invasive surgery and restenosis of BMS, but the
argest factors have probably been logistical and political.
e have performed 112 hybrid CABG/PCI procedures
ver about a 2-year period in our hybrid catheterization
aboratory/operating room (Zhao DX, Leacche M, Balaguer
M, Boudoulas KD, Damp JA, Greelish JP, Byrne JG,
npublished data April 2005 to July 2007). There were no
eaningful differences between risk-adjusted outcomes.
inimally invasive CABG surgery is limited by longer
perating time, late wound complications, and more late
ain because of rib retraction (39). Perhaps the greatest
imitations, however, are the technical demands placed on
he surgeon. Because MIDCAB and TECAB are techni-
ally demanding, anastomosis patency in the learning curve
ay be lower than conventional approaches. This is why we
elieve intraoperative imaging may eventually become man-
atory for these procedures to become more commonplace.
n our hybrid suite, all MIDCAB procedures undergo
outine intraoperative completion angiography before chest
losure (Fig. 2). The most experienced investigators report
atency rates of the MIDCAB LIMA–LAD graft between
2% and 100% within 6 months of the procedure (23,30).
nother limitation of hybrid coronary revascularization is
tent restenosis and the need for repeat revascularization
ith BMS. In hybrid series, the stent restenosis at 6 months
s 2.3% to 23% with an average across the literature of 11%
Table 1). The high rate seen in these series may be
xplained by the low use of DES. Moreover, in most of the
arlier series of MIDCAB, percutaneous transluminal cor-
nary angioplasty of the coronary vessels without stenting
as the strategy adopted. In more recent series of MID-
AB, using only DES, Kon et al. (32) have reported at 1
ear stent patency rates of 97%. In the RAVEL (A
andomized Comparison of a Sirolimus-Eluting Stent
ith a Standard Stent for Coronary Revascularization) trial
40), the DES have shown excellent survival free from TLR
t 1, 3, and 5 years (99%, 93.8%, 89.7%), respectively. These
xceptional results may not be reflected in the practice of
ost interventional cardiologists and surgeons because pat-
ern of lesions may be more complex, such as bifurcated
esions, small vessels, or long lesions. Furthermore, over the
ast year, concern for higher incidence of late stent throm-
osis compared with BMS has clouded the picture of DES
41,42). However, new data (43) from randomized trials
nd real-world registries have shown that DES are safe and
fficacious.
-Staged Hybrid Versus 1-Stop Hybrid CABG/PCI
ll hybrid procedures are staged, the only distinction being
he duration of the staging. For purposes of this discussion,
-staged will be defined as PCI and CABG performed in 2
ifferent operative suites, the 2 procedures separated by
ours, days, or weeks, whereas 1-stop refers to hybrid
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462ABG/PCI performed in a hybrid suite in 1 setting,
taged by minutes. The appeal of the latter is multifold,
ncluding improved logistics, lower cost, and improved
atient satisfaction.
In 2-staged hybrid procedures, performing PCI before
ABG surgery allows aggressive multivessel stenting be-
ause if a complication arises or PCI is not successful,
ABG can be performed later. The main disadvantages of
his approach are performing PCI in an unprotected envi-
onment without the benefit of a LIMA–LAD graft, and
ater performing CABG under powerful antiplatelet agents,
s well as no mid-term angiographic controls of the LIMA–
AD graft unless a third procedure is done—the comple-
ion angiogram before hospital discharge.
Performing PCI after CABG avoids antiplatelet-related
leeding complications during CABG, has the advantage of
protected environment with a LIMA–LAD graft, and the
IMA graft patency can be verified at the time of PCI. In
he event of PCI complication/failure, however, a second,
igher-risk operation needs to be performed. The latter
hould be rare, however, as emergent CABG after PCI has
Table 1. Results of Hybrid Coronary Revascularization
Author (Ref. #) Year
Patients
(n)
Mortality
(30-Day)
In-Hospi
Morbidi
(%)
MIDCAB  PTCA
Lloyd et al. (20) 1999 18 0 11
Isomura et al. (21) 2000 37 0 NA
de Cannière et al. (22) 2001 20 0 15
Presbitero et al. (23) 2001 42 2 12
Cisowski et al. (24) 2002 50 0 4
Stahl et al. (25) 2002 54 0 0
MIDCAB  PTCA  PCI
Angelini et al. (1) 1996 6 0 NA
Lewis et al. (26) 1999 14 0 21
Wittwer et al. (27) 2000 35 0 0
Riess et al. (28) 2002 57 0 7
MIDCAB  PCI
Zenati et al. (29) 1999 31 0 6
Us et al. (30) 2006 17 0 0
Gilard et al. (31)‡ 2007 70 1.4 4.2
Kon et al. (32)‡ 2007 15 0 0
TECAB
Lee et al. (33) 2004 6 0 0
Davidavicius et al. (34) 2005 20 0 0
Kiaii et al. (35) 2005 1 0 0
Katz et al. (36)§ 2006 27 0 3.7
Vassiliades et al. (37)‡ 2006 47 0 0
Bonatti et al. (38) 2007 5 0 0
*Calculated on a per-patient basis. †TLR including revision or stenting of LIMA graft. ‡All DES used
BMS bare-metal stent; DES drug-eluting stent; LIMA left internal mammary artery; MIDCA
coronary intervention; PTCA percutaneous transluminal coronary angioplasty; TECAB totally elow incidence (1%) (44). For these reasons, most burgeons and cardiologists who practice 2-staged hybrid
rocedures have adopted the strategy of CABG first, fol-
owed a few days later by PCI.
Whether PCI is performed before or after CABG, in
-staged hybrid procedures, 2 teams, 2 costs, longer hospital
tays, logistical challenges, and potential risks related to
andoffs must be considered, and many patients just do not
ant to undergo 2 procedures. For these reasons, we believe
1-stop approach may be preferable.
When taking into account the limitations of 2-staged
ybrid procedure, combining surgery and PCI in 1 proce-
ure may be a superior approach because there is excellent
onitoring, any complications can be resolved in 1 setting,
nd graft patency can be confirmed. Potential limitations
nclude the use of antiplatelet agents, the unknown response
f DES to heparin reversal with protamine, and the need to
uild an especially dedicated hybrid room with capabilities
f both a complete operating room and a procedural suite
Fig. 3). Inconsistent data have been reported regarding the
ffect of clopidogrel in patients undergoing hybrid proce-
ures. Some investigators have reported an increase in
LIMA
Patency
(Immediate)
(%)
PTCA/Stent
Restenosis
(6 Months)
(%)
Mean
Follow-Up
(Months)
Event-Free
Survival
(%)
100 6 (TLR)* 18 89
100 NA 0–24 92
100 5 24 95
92 14 (TLR)† 18 83
100 10 12 87
100 NA 12 87
NA NA NA NA
100 0 1–44 93
100 7 11 87
98 24 24 NA
100 10 11 90
100 18 21 87
NA 2.3 33 97
100 3 12 93
NA 16 12 NA
100 0 19 100
100 0 6 100
96 (3 months) 30 (BMS), 23.5 (DES) 3 70
99 6.6 7 90
100 0 6 100
. §DES (63% of patients).
inimally invasive direct coronary artery bypass grafting; NA not applicable; PCI percutaneous
pic coronary artery bypass; TLR target lesion revascularization.tal
ty
for PCI
Bmleeding (45), whereas others have shown no differences
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46332,38). Because the effect of clopidogrel is time-dependent
nd dose-dependent, a tailored administration may be
elpful to reduce the incidence of bleeding complications.
on et al. (32) in a hybrid series of 15 patients administered
00 mg clopidogrel on arrival in the intensive care unit.
owever, they did not reverse heparin at the end of the
urgery. The investigators report a mean of 0.2  0.4 blood
nit/patient transfusion rate, no re-exploration for bleeding,
nd no stent thrombosis.
The effect of reversal of heparin on stent patency is
nknown. When CABG is performed on-pump, the anti-
latelet effects of cardiopulmonary bypass may help prevent
tent thrombosis. However when CABG is performed
ff-pump, the effects of heparin reversal are unknown.
ecause off-pump coronary artery bypass (OPCAB) has
een reported to be associated with increased state of
ypercoagulability (32), this coupled with a lower dose of
lopidogrel to attempt to limit bleeding at the time of
ABG may increase the likelihood of stent thrombosis.
ore data are needed to make firm recommendations.
PCAB Versus MIDCAB
he number of hybrid (MIDCAB/PCI) procedures in
ome centers has decreased over an increase of OPCAB
rocedures (28). The OPCAB procedure compared with
n-pump surgery has lower blood utilization, lower mortal-
ty in some high-risk patients (46), and lower costs (47).
Figure 2. Completion Angiogram
A completion angiogram of a LIMA graft to the LAD after MIDCAB proce-
dure. Abbreviations as in Figure 1.he Beating Heart Against Cardioplegic Arrest trial (48)as shown 2% mortality and a TLR rate of 2% at 2 years.
nother trial (47) has confirmed low TLR rates (3.4%) and
igh graft patency rates (91%) at 1 year. Although OPCAB
as lower costs compared with hybrid procedures and a
-staged hybrid procedure requires 2 procedures and 2
ospital fees, and the need for potential repeat revascular-
zation may be higher because of stent restenosis (22),
IDCAB procedures remain appealing. With minimal
ardiac manipulation, the LIMA–LAD graft can be con-
tructed and this can be done safely in patients with low
entricular ejection fraction with avoidance of aortic manip-
lation and of side-bite clamping used to construct the
roximal anastomosis. Another potential benefit is avoid-
nce of use of SVG, which limits the longevity of CABG
urgery. It is likely that as technology improves the dura-
ility of DES, SVGs will become less ideal. We envision a
ierarchy of value of revascularization choices: all high-
rade proximal LAD lesions should probably be treated
ith a LIMA–LAD. After that, depending on the location
nd complexity of the lesion, a right internal mammary
rtery graft, a DES, SVG, BMS, or medical therapy alone
ay be preferable. Furthermore, some centers have reported
iminished SVG patency rates after OPCAB, citing the
ypercoagulability status in OPCAB to explain this phe-
omenon (49). This may make hybrid CABG/PCI more
ppealing.
ybrid Valve/PCI
lternative approaches to standard sternotomy for valve
urgery have been advocated to reduce operative mortality
nd morbidity, speed recovery, and improve cosmetics.
hese approaches include partial sternotomies (50) and
ini-thoracotomies (51). Concomitant coronary artery dis-
Figure 3. Hybrid Operating RoomA hybrid operating room.
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464ase has been a contraindication to such approaches because
oncomitant CABG, and therefore sternotomy, would be
andatory. Approaching coronary disease with PCI, which
ay actually be superior to SVG, has given the opportunity
o expand the indications for minimally invasive valve
urgery to patients with concomitant coronary disease.
inimally Invasive Versus
onventional Valve Surgery
inimally invasive valve surgery refers to a collection of
echniques in which several alternative incisions to sternot-
my (Fig. 4A) have been used. For minimally invasive aortic
alve surgery, upper hemi-sternotomy (Fig. 4C) is the
urrent standard (52,53). For mitral valve surgery, 2 ap-
roaches are used, including small right mini-thoracotomy
Fig. 4B) or lower hemisternotomy (Fig. 4D) (50,51,54).
he robotic and video-assisted mitral valve procedure can be
erformed through a right mini-thoracotomy approach
55). Few cases have been reported for robotic aortic valve
urgery (56).
To provide extrathoracic cardiopulmonary bypass, for
eripheral cannulation or direct aortic cannulation, special-
zed arterial and venous cannulas are needed; for antegrade
r retrograde cardioplegia, special endovascular cannulas
nd catheters are needed; and for aortic cross-clamp, spe-
ially designed endovascular aortic occlusion or transtho-
acic aortic cross-clamp are needed (50–52,55,57).
Large series of minimally invasive aortic and mitral valve
urgery have reported reduced postoperative pain, faster
ecovery, less utilization of autologous blood, and superior
osmetic results (50–54). Reports that have compared
inimally invasive valve surgery and conventional surgery
Figure 4. Incisions for Valve Surgery
(A) Median sternotomy (aortic, mitral, or tricuspid valve). (B) Right thoracotom
hemi-sternotomy (mitral or tricuspid valve). Figure illustration by Rob Flewell.ave documented relatively consistent reduction in blood
tilization and shorter hospital stay (52,58–60).
Because of the aforementioned benefits of minimally
nvasive valve surgery, recently some groups have combined
inimally invasive valve surgery with PCI for combined
alve/CABG surgery (45,54,57).
ationale of Hybrid Valve/PCI
he rationale behind hybrid valve surgery is to substitute
CI for CABG (typically substituting PCI for SVG) to
onvert a combined valve/CABG procedure requiring ster-
otomy into an isolated valve procedure, which can be
erformed using minimally invasive techniques. We see 3
ettings in which this may be of benefit.
ABG patient with poor conduit for CABG surgery. Poor or
imited vein graft quality combined with poor target vessel
uality is one of the reasons SVG failure at 1 year is as high
s 30% (61). In the presence of such conditions, a PCI with
ES may be a better option.
onvert high-risk valve/CABG surgery into a lower-risk iso-
ated valve. Traditional valve/CABG surgery has twice the
ortality of isolated valve surgery (62,63). In a large series
f patients from the New York Cardiac Surgery Reporting
ystem from 2001 to 2003 on approximately 10,000 pa-
ients, the mortality for isolated valve surgery was 4.4%
ersus 9% for valve and concomitant coronary surgery (62).
n high-risk patients with multiple comorbidities such as
ncreased age, low ejection fraction, morbid obesity, and
ulmonary and renal dysfunction, it may even be higher.
hus, combining 2 low-risk strategies, PCI (1% mortality in
he elective settings) with minimally invasive approaches
0.7% to 2% mortality range) (50) is very appealing to
ral or tricuspid valve). (C) Upper hemi-sternotomy (aortic valve). (D) Lowery (mit
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465educe the overall operative risk (45). Brinster et al. (57)
eported on 18 patients, mean age 76 years, with combined
oronary artery and aortic valve disease. Avoiding high-risk
ABG/valve surgery in this high-risk elderly population, a
trategy of PCI with DES followed within 24 h by mini-
ally invasive aortic valve replacement was used. The
nvestigators report 5.5% in-hospital mortality and 95%
atient survival at 19-month follow-up.
Hybrid valve surgery is especially suitable for patients
ith acute coronary syndrome and known valve disease. In
his approach, usually PCI is performed first to the culprit
esion, stabilizing the coronary lesion, and then, during the
ame hospital stay, the valve lesion is addressed 5 to 7 days
fter the initial PCI (45). This approach converts an
mergent/urgent concomitant coronary and valve surgery
nto a more elective isolated valve surgery. We reported on
his approach in 26 patients with known combined coronary
rtery disease and valve disease. Of these patients, 92% had
cute coronary syndrome, 50% had unstable angina, 42%
ad acute myocardial infarction, and 15% were in cardio-
enic shock. The predicted Society of Thoracic Surgeons
ortality, had conventional valve/CABG been performed at
he time of PCI, for this group was 22%. The observed
ortality was instead only 3.8% (45).
onvert reoperative valve/CABG into reoperative isolated
alve surgery. Two broad scenarios for this strategy include
he need for reoperative valve re-replacement for structural
alve degenerations after biological valve replacement in the
etting of known coronary disease and the need for primary
ative valve surgery late after CABG. Typical scenarios for
he latter include late native aortic valve stenosis after
ABG in which the gradient at the time of original CABG
as thought to not warrant concomitant aortic valve re-
lacement (64) or late ischemic mitral regurgitation after
ABG in which avoiding sternotomy is particularly appeal-
ng. Both these sets of patients typically have a patent
IMA–LAD graft, which makes resternotomy particularly
azardous. The benefits of a hybrid approach are to perform
CI to a graft or native vessel coronary artery disease,
hereby avoiding the reoperative CABG component. It just
akes no sense to dissect the entire heart, placing patent
rafts at risk, to place an SVG on an obtuse marginal target.
n valvular patients, because of the cardiomegaly which can
ake the heart closer to the posterior table of the sternum
y displacing it anteriorly, the re-entry has a 4% incidence of
omplication (65). Moreover, the exposure of the mitral
alve in redo sternotomy can be difficult because the heart is
xed anteriorly and cannot drop into the left chest, and in
he presence of a prosthetic aortic valve, the fibrous skeleton
s fixed and the heart cannot be rotated, making exposure
ery difficult and limited. With the minimally invasive right
horacotomy approach, the visualization of the mitral valve
s excellent (54). aIn patients with previous bypass grafts, careful dissection
o avoid injury to a patent LIMA–LAD graft is necessary
ecause of the high mortality (50%) that such a complica-
ion carries (66). Embolization to the native coronary
ystem of manipulated diseased but patent SVGs increases
ortality and morbidity (67). Overall, reoperative surgery,
nless for isolated aortic valve surgery, has an increased risk
f mortality, morbidity, sternal dehiscence, and bleeding
65,68).
imitations of Hybrid Valve/PCI
s for coronary hybrid CABG/PCI, there is concern
egarding the impact of antiplatelet agents on bleeding after
urgery. In the literature, one hybrid valve series (45) reports
ncreased chest tube output, blood requirements (85% of
atients received a blood transfusion), and reoperation for
leeding (8%), whereas another series (57) reports low chest
ube output, low incidence of reoperation for bleeding (0%),
nd lower blood utilization (44% of patients). Both series
re retrospective studies with small numbers of patients.
he main difference between these series is the timing of
he surgery, in the first within 5 to 7 days after PCI and in
he second within 24 h. It may be hypothesized that the
ifferent timing of loading of clopidogrel has an impact on
he different incidence of bleeding. Another way to decrease
he risk of bleeding is to shorten the staging of PCI and
urgery within 6 h, so that clopidogrel effects are just
eginning to take effect once the surgery is completed. This
pproach, however, requires a specially designed suite, the
ybrid operating room (Fig. 3), because if performed in 2
eparate suites, it will require holding an operating room
nd double fee for the catheter laboratory and the operating
oom. We have performed 31 1-stop hybrid valve/PCI
rocedures (unpublished data) in our hybrid suite, with
mproved mortality rates compared to the Society of Tho-
acic Surgeons predicted outcomes. Finally, if significant
roximal LAD disease is present, the patient should prob-
bly undergo LIMA–LAD and valve surgery via a conven-
ional sternotomy. If the patient is so high-risk that ster-
otomy is thought contraindicated, PCI to the LAD
ombined with minimally invasive valve surgery is probably
easonable.
Limitations of minimally invasive valve surgery are: the need
or a learning curve; operative times can be longer, especially at
he beginning; it requires the surgeon to work through smaller
ncisions with sometimes different instruments than usual; and
he exposure of the valve can be initially difficult. Moreover, the
nstitution of cardiopulmonary bypass and myocardial protec-
ion can be more time consuming and troublesome. Satisfac-
ory de-airing may be difficult because of the limited access to
he aorta or the apex of the heart. This has raised concern
mong some investigators of increased risk of neurological
dverse events (69). Another concern is the inability to fully
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466isualize the heart in case of heart distension, thus relying
lmost completely on transesophageal echocardiogram to
onitor heart distension.
ybrid Atrial Fibrillation Procedures:
ombined Endocardial/Epicardial Approach
urgical treatment of AF is usually reserved for patients
ndergoing either valve or coronary surgery. Lesions sets are
reated either surgically with incisional atriotomies (the
aze procedure) (70) or through epicardial or endocardial
blation. The latter can be achieved though cryoablation or
adiofrequency.
Isolated treatment for AF is usually pharmacological or
atheter-based ablation, or a combination of both for
esistant AF (71). Further development of the closed-chest
r minimally invasive technique by surgeons has expanded
he horizon to lone epicardial atrial fibrillation surgery,
erhaps in conjunction with percutaneous endocardial tech-
iques. The surgical approaches have the advantages of
eing faster and more extensive than percutaneous ap-
roaches. However, some lesions may be more easily created
y percutaneous approach. Ideally, this would be done in a
pecially designed hybrid electrophysiologist operating
oom to further modify treatment or to assess effects of
esions created (72). Some groups already have been using
his strategy in a staged fashion (73).
ybrid Approach for Complex Thoracic
ortic Aneurysms: Debranching Procedures
ombined With Endovascular Stenting
urrently, the treatment of complex thoracic aneurysms is
ostly endovascular, whereas traditionally, open repair is
eserved for cases that are not suitable for endovascular
tenting because of anatomic characteristics of the aneu-
ysm. A combination of surgical and endovascular treatment
s reserved for a highly selected group of patients who are
oo high-risk for surgical open repair and have inadequate
ength of the landing zone (distal or proximal) for deploy-
ent of endovascular stenting. In the treatment of aortic
rch aneurysm, an aorto-innominate bypass is typically
onstructed followed by bypass of the head vessels of this
raft, which allows proximal extension of stent grafts into
he transverse aortic arch. The feasibility of such procedures
as been reported with acceptable mortality and morbidity,
lbeit with a higher incidence of early endovascular leaks
74–76). The natural history of these endovascular leaks
eems favorable, with high resolution at 6 months of
ollow-up (90%).
More often debranching procedures are used to treat
omplex thoracoabdominal aneurysms. In these hybrid pro-
edures, bypasses and/or transposition of visceral vessels are csed to enable distal extension in the visceral portion of the
orta of the stent graft. Experienced centers report a high
eriprocedural success rate (90%) with acceptable mortality
ates (between 3% and 24%, average of 13%) (77–80).
hese procedures are long and complex, and there is
oncern regarding the long-term patency of prosthetic grafts
sed for visceral and renal revascularization (80).
onclusions
ybrid CABG/PCI is performed in only few centers, but
ay experience renewed interest as technology makes DES
etter than SVG. Hybrid CABG/PCI may be reserved for
igher-risk patients who are not candidates for conventional
ABG. In these patients, a MIDCAB with LIMA–LAD
nd PCI to non-LAD vessels may help reduce risk. With
he advent of DES and lower stent restenosis rate compared
ith BMS, DES may be a valid alternative to SVGs as the
verall patency rate is superior at 1 year for the DES.
Hybrid valve/PCI represents an excellent alternative to
onventional valve/CABG in some high-risk patients, par-
icularly those who presents after acute coronary syndromes,
nd in some patients who require reoperative valve surgery.
Hybrid atrial fibrillation treatments combine percutane-
us endomyocardial and surgical epicardial approaches.
ome centers have already tried to combine surgical and
ercutaneous ablation in a staged fashion. There may be a
ole for a hybrid electrophysiologist laboratory for these
rocedures to be performed in 1 setting with intraoperative
apping.
Aortic debranching procedures enable deployment of
ndovascular stents with inadequate length of the landing
one. Frequently, these patients are high-risk candidates
or the performance of open surgical intervention and
ecause of aneurysm anatomy are not candidate for
ndovascular repair. More commonly, these procedures are
eserved for the treatment of complex thoracoabdominal
neurysm.
The future of cardiac surgery and interventional cardiol-
gy is headed toward a merger of the fields for tailored
pproaches to patients who present with complex heart
isease. Although the ability to offer hybrid approaches will
epend on technological advancements, improved percuta-
eous and minimally invasive techniques, and the availabil-
ty of a hybrid suite, the true barrier to entry is the ability of
ardiologists and cardiac surgeons to work together (81), to
ngage in “hybrid thinking” (82) with close collaboration
etween the 2 specialties. We believe the willingness and
bility to create this collaborative culture is the largest
arrier to creating a successful hybrid program. We are all
ardiovascular interventionalists, with different tools.
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